Related Experiment Video

Updated: Oct 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Erdafitinib for locally advanced or metastatic urothelial carcinoma

Arlene O Siefker-Radtke1, Yohann Loriot2

  • 1Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|February 11, 2022
PubMed
Abstract

No abstract available in PubMed .

Keywords:
FGFR alterationefficacyerdafitinibsafetyurothelial carcinoma

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
06:39

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Published on: November 22, 2019

7.8K

Related Experiment Videos

Last Updated: Oct 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
06:39

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Published on: November 22, 2019

7.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

Articles linked to this work by shared authors, journal, and citation graph.

Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial.

European urology oncology·2026

Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.

Future oncology (London, England)·2026

Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials.

European journal of cancer (Oxford, England : 1990)·2026

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

The New England journal of medicine·2026

Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

JCO precision oncology·2026

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

A qualitative evaluation of a fracture liaison service in an academic healthcare system.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Improving the consistency and efficiency of auxiliary labeling using EHR-integrated color printing technology.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Implementation of a passive bin-based perpetual medication inventory model within ambulatory clinics at an academic medical center.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Recent and anticipated novel drug approvals (3Q 2026 through 2Q 2027).

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Impact of an electronic documentation system on timeliness and ancillary task completion.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Thigh abscess following alternate-site continuous glucose monitoring sensor placement.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Regulatory roles of pyroptosis-associated lncRnas in breast cancer progression and immune microenvironment.

Cell cycle (Georgetown, Tex.)·2026

Insights Into the Mechanisms of Biological Aging That Guide Translational and Clinical Research.

Aging medicine (Milton (N.S.W))·2026

Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.

International journal of nanomedicine·2026

Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.

International journal of pharmaceutics: X·2026

Enhanced anticancer efficacy of Pa-MAP 1.9 peptide-coated silver nanostars on breast cancer cells.

Materials today. Bio·2026

Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer.

Materials today. Bio·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us